Abstract
Epidermal growth factor (EGF) is synthesized in the pancreas and diabetic animals have low levels of EGF. However, the role of EGF in regulating the major function of the pancreas, insulin secretion, has not been studied. Here, we show that EGF rapidly increased insulin secretion in mouse pancreatic islets, as well as in a pancreatic β-cell line. These events were dependent on a Ca2+ influx and phospholipase D (PLD) activity, particularly PLD2, as determined using pharmacological blockers and molecular manipulations such as over-expression and siRNA of PLD isozymes. In addition, EGF also increased plasma insulin levels and mediated glucose lowering in normal and diabetic mice. Here, for the first time, we provide evidence that EGF is a novel secretagogue that regulates plasma glucose levels and a candidate for the development of therapeutics for diabetes.
| Original language | English |
|---|---|
| Pages (from-to) | 1593-1604 |
| Number of pages | 12 |
| Journal | Journal of Cellular and Molecular Medicine |
| Volume | 12 |
| Issue number | 5A |
| DOIs | |
| State | Published - Sep 2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Epidermal growth factor
- Glucose homeostasis
- Insulin secretion
- Phospholipase D2
Fingerprint
Dive into the research topics of 'Epidermal growth factor increases insulin secretion and lowers blood glucose in diabetic mice'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver